Epic Sciences announces six pharma circulating tumor cell collaborations.
Epic Sciences, a privately held cancer diagnostics company, announced today that it has established collaborations with six pharmaceutical partners employing Epic's proprietary Circulating Tumor Cell ("CTC") technology. The partners include two of the top four pharmaceutical companies worldwide. In total, the collaborations include 12 clinical trials involving over 40 distinct projects measuring 18 different protein or genomic tumor markers on CTCs. The clinical trials include sites in the US, Europe and Asia with over 1500 patients and 2500 clinical samples in prostate, lung, breast, pancreatic and ovarian cancers.